NASDAQ:COCP Cocrystal Pharma Q1 2026 Earnings Results & Report $1.07 0.00 (0.00%) Closing price 10/9/2026 03:58 PM EasternExtended Trading$1.08 +0.00 (+0.47%) As of 10/9/2026 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Cocrystal Pharma missed analyst earnings expectations and met on revenue in its Q1 2026 results, released May 15, 2026. The company reported EPS of -$0.17 versus the -$0.15 consensus estimate, while revenue of $0.23 million matched the $0.23 million estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 15, 2026TimeBefore Market Opens Cocrystal Pharma EPS ResultsActual EPS-$0.17Consensus EPS -$0.15Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersCocrystal Pharma Revenue ResultsActual Revenue$0.23 millionExpected Revenue$0.23 millionBeat/MissMet ExpectationsYoY Revenue GrowthN/AUpcoming EarningsCocrystal Pharma's next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Cocrystal Pharma Q1 2026 Earnings FAQ Did Cocrystal Pharma beat earnings estimates for Q1 2026? Cocrystal Pharma (NASDAQ:COCP) reported earnings of -$0.17 per share for Q1 2026, missing the consensus estimate of -$0.15. The report was announced on Friday, May 15, 2026. What was Cocrystal Pharma's revenue for Q1 2026? Cocrystal Pharma reported revenue of $0.23 million for Q1 2026, against a consensus estimate of $0.23 million. When is Cocrystal Pharma's next earnings date? Cocrystal Pharma's next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cocrystal Pharma on the company's earnings history page. Cocrystal Pharma Earnings HeadlinesBrokers Set Expectations for COCP Q4 Earnings2 hours ago | americanbankingnews.comHead-To-Head Survey: Cocrystal Pharma (NASDAQ:COCP) vs. Bristol Myers Squibb (NYSE:BMY)October 2, 2026 | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and TreatmentSeptember 9, 2026 | globenewswire.comCOCP: $5 Million Private Placement with OPKO HealthAugust 20, 2026 | finance.yahoo.comCocrystal Pharma strengthens board with antiviral expert appointmentAugust 19, 2026 | theglobeandmail.comSee More Cocrystal Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email. Email Address About Cocrystal PharmaCocrystal Pharma (NASDAQ:COCP) is a clinical-stage biotechnology company focused on discovering and developing antiviral therapies. The company uses a structure-based drug discovery platform to identify small-molecule compounds designed to interfere with essential viral replication proteins. Its research programs have targeted a range of viral diseases, including influenza A, norovirus and coronaviruses. Cocrystal’s development activities have included orally administered antiviral candidates intended for the treatment or prevention of viral infections, with programs advancing through a combination of preclinical research and clinical development. Founded in 2007 and formerly known as BioZone Pharmaceuticals, the company adopted the Cocrystal Pharma name after combining with Cocrystal Discovery in 2015. Cocrystal is headquartered in Bothell, Washington, and its research and development efforts are directed primarily toward potential antiviral treatments for markets in the United States and internationally.View Cocrystal Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
